RAPT Therapeutics, Inc. (RAPT) Misses Q2 EPS by 56c

RAPT Therapeutics, Inc. (NASDAQ: RAPT) reported Q2 EPS of ($0.65), $0.56 worse than the analyst estimate of ($0.09).

For earnings history and earnings-related data on RAPT Therapeutics, Inc. (RAPT) click here.

You May Also Be Interested In

• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Trump on Iran: we're trying to work out a deal that's fair
• SPS Commerce hires Morgan Stanley, explores sale - Reuters